Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection

OBJECTIVES: Fidaxomicin was non-inferior to vancomycin with respect to clinical cure rates in the treatment of Clostridium difficile infections (CDIs) in two Phase III trials, but was associated with significantly fewer recurrences than vancomycin. This economic analysis investigated the cost-effect...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Nathwani, Dilip, Cornely, Oliver A., Van Engen, Anke K., Odufowora-Sita, Olatunji, Retsa, Peny, Odeyemi, Isaac A. O.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2014
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4195473/
https://ncbi.nlm.nih.gov/pubmed/25096079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dku257
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk